Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: U.S. IPOs Drag, Weighed Down by Brexit, Other Uncertainty <i>(Bloomberg BNA)</i>

PRESS: U.S. IPOs Drag, Weighed Down by Brexit, Other Uncertainty (Bloomberg BNA)

Related Content

Bio-Thera Solutions Expands Partnership with SteinCares to Market Two Biosimilars in LATAM

FDA Approves New Biologic Cancer Treatments

FDA Designates Intellia’s Nexiguran Ziclumeran (nex-z) as a Regenerative Medicine Advanced Therapy

Intas Expands Cancer Therapy Biosimilar Portfolio

Recent Biologics Deals

Six Hot Trends in Life Sciences for 2025

Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2024-2025

Biocon Announces FDA Approval of Ustekinumab Biosimilar

Goodwin Rare Disease Symposium 2025

Goodwin CLE Week 2025

Palleon Pharmaceuticals and Henlius Enter into Collaboration to Advance Glycan Editing as a Treatment for Autoimmune Diseases

Goodwin Advises Duality Biologics to Enter Exclusive Option Agreement With GSK for a Novel Antibody-drug Conjugate (DB-1324) for Up to $975 Million

Goodwin Advises VelaVigo on Exclusive Option Agreement with Avenzo to License Nectin4/TROP2 Bispecific Antibody-Drug Conjugate for Up To $750 Million

Antag Therapeutics Closes €80 Million Series A Financing

AQEMIA Raises $38 Million

Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.

Life Sciences

Technology

Capital Markets

Public Company Advisory Practice